Olema Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of targeted therapies for breast cancer. The company’s lead product candidate, palazestrant (formerly OP-1250), is an orally available small molecule that acts as both a complete estrogen receptor antagonist and a selective estrogen receptor degrader, currently in late-stage clinical trials for estrogen receptor-positive, human epidermal growth factor receptor 2-negative metastatic breast cancer. A second candidate, OP-3136, is a KAT6 inhibitor in Phase 1 clinical trials for breast and other solid tumors. Olema collaborates with Novartis Pharma AG for drug supply in the OPERA-02 trial and relies on third parties for manufacturing. Founded in 2006, the company targets patients with endocrine-driven cancers and mechanisms of acquired resistance.

Summarised from the company's own disclosures, fiscal year ended Mar 2026

Industry Biotechnology Homepage olema.com
Sector Healthcare IR page ir.olema.com
Tags
breast cancer, estrogen receptor, small molecule, kat6 inhibitor, clinical-stage, endocrine therapy, metastatic cancer, solid tumors, palazestrant, OP-1250, OP-3136, OPERA-01, OPERA-02, Novartis Pharma AG
Press page —

Metrics

Valuation  
Market cap $ 755.587M
Market cap (USD) $ 755.587M
P/E -4.06
PEG —
P/BV 1.75
P/S —
P/OCF -4.59
P/FCF -5.15
Dividend yield —
Turnover / mcap —
Returns  
ROE -36.6%
ROI -33.7%
ROIC -27.8%
Profit margin —
Growth  
Revenue growing —
Profits growing No
Revenue up 3y —
Revenue up 5y —
Earnings growth 3y (net profit CAGR) —
Quality  
Profitable No
Margin expanding —
Buying back stock No
Diluting (TTM) Yes
Debt/Equity 0.63%
Podcast bulls (TTM) Sign up
Podcast bears (TTM) Sign up
Podcast sentiment (TTM) Sign up
Podcast sentiment % (TTM) Sign up
News sentiment (TTM) 7
Quality score -76.9%
Insiders  
Buys, 1w Sign up
Buys, 1m Sign up
Buys, 1y Sign up
Sells, 1w Sign up
Sells, 1m Sign up
Sells, 1y Sign up

Sign up to see this company's insider trades

Figure FY 2025 FY 2024 FY 2023 FY 2022 FY 2021 FY 2020
Assets 533.43M 450.979M 276.945M 215.645M 295.945M —
Net profit -162.451M -129.474M -96.655M -104.787M -71.096M 0
Free cash flow -146.716M -104.51M -83.727M -82.428M -52.265M —

Figure FY 2025 FY 2024 FY 2023 FY 2022 FY 2021 FY 2020
Share price 25 5.83 14.03 2.45 9.36 —
Price performance 12m 3.29 -0.58 4.73 -0.74 -0.81 —

Filed figures

Figure Dec 2018 Dec 2019 Dec 2020 Dec 2021 Dec 2022 Dec 2023 Dec 2024 Dec 2025
Balance sheet detail
Lease liabilities (USD) — — — 3.29M 2.57M 2.42M 1.43M 1.19M
Cash and deposits (USD) 3.15M 68,000 339M 13.8M 23.7M 68.5M 139M 48.3M
Right-of-use assets (USD) — — — 3.25M 2.5M 2.29M 1.31M 1.15M
Cash flow detail
Operating cash flow (USD) — -3.08M -19.9M -50.7M -82.1M -83.7M -104M -147M
Purchases of property, plant and equipment (USD) — — -56,000 -1.58M -363,000 — -159,000 —
Change in payables (cash effect) (USD) — 810,000 -220,000 -683,000 351,000 2.32M 2.51M 4.6M
Share-based compensation (USD) — — 3.11M 15.9M 18.8M 17.3M 22.6M 17.6M
Free cash flow (OCF - PPE - intangibles) (USD) — — -19.9M -52.3M -82.4M — -105M —
Income detail
Research and development expense (USD) — 3.92M 13.7M 51.1M 82.3M 86.1M 125M 158M
↳ 5y CAGR +99.7% +63.0%
Total comprehensive income (USD) — -4.32M -22.1M -71.2M -106M -94.5M -130M -162M
Comprehensive income to owners (USD) — -4.32M -22.1M -71.2M -106M -94.5M -130M -162M
Reported Feb 28, 2022 Feb 28, 2022 Feb 28, 2022 Feb 28, 2022 Mar 9, 2023 Mar 11, 2024 Mar 18, 2025 Mar 16, 2026

Sign up to see institutional holdings

Sign Up

Podcast Mentions

Sign up to see podcast mentions and sentiment

Sign Up

Olema Oncology Announces Corporate Name Change Bull 0 Bear 0 Routine

SAN FRANCISCO, November 12, 2026 (Globe NewsWire) – Olema Oncology, Inc. (formerly Olema Pharmaceuticals, Inc.) (“Olema” or “Olema Oncology”, Nasdaq: OLMA), a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of targeted therapies for breast cancer and beyond, announced that, effective today, it has changed its corporate name from “Olema Pharmaceuticals, Inc.” to “Olema Oncology, Inc.” pursuant to the Company’s Eighth Amended and Restated Certificate of Incorporation filed with the Secretary of State of Delaware.

The Company’s common stock will continue to be listed and trade on the Nasdaq Global Select Market under the ticker symbol “OLMA.” Pursuant to Delaware law, no action was required by stockholders of the Company to effect the name change. Stock certificates reflecting the prior corporate name will continue to be valid.

About Olema Oncology

Olema Oncology is a clinical-stage biopharmaceutical company committed to transforming the standard of care and improving outcomes for patients living with breast cancer and beyond.

•On track to announce top-line data from the pivotal Phase 3 OPERA-01 trial in the first quarter of 2027

•Continued strong enrollment in the pivotal Phase 3 OPERA-02 trial and the Phase 1b/2 study of OP-3136

•Appointed Jason O’Byrne, MBA, as Chief Financial Officer

•Ended the third quarter with $413.8 million in cash, cash equivalents, and marketable securities

SAN FRANCISCO, November 10, 2026 (Globe NewsWire) – Olema Pharmaceuticals, Inc. (“Olema” or “Olema Oncology”, Nasdaq: OLMA), a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of targeted therapies for breast cancer and beyond, today reported financial and operating results for the third quarter ended September 30, 2026.

“As we approach top-line data from our pivotal Phase 3 OPERA-01 trial in the first quarter of 2027, we remain confident in palazestrant’s potential to emerge as a differentiated endocrine therapy in second- and third-line metastatic breast cancer,” said Sean P. Bohen, M.D., Ph.D., President and Chief Executive Officer of Olema Oncology. “Turning to our pivotal Phase 3 OPERA-02 trial in first-line metastatic breast cancer, momentum continues to build.

November 4, 2026

PDF Version

SAN FRANCISCO, Nov. 04, 2026 (GLOBE NEWSWIRE) -- Olema Pharmaceuticals, Inc. (“Olema” or “Olema Oncology”, Nasdaq: OLMA), a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of targeted therapies for breast cancer and beyond, today announced it will present clinical data from the Phase 1b/2 study of OP-3136 in combination with fulvestrant, the Phase 1b/2 study of palazestrant in combination with everolimus, and the Phase 1b study of palazestrant in combination with atirmociclib in poster presentations at the San Antonio Breast Cancer Symposium (SABCS) taking place December 8-11 in San Antonio, TX.

Poster Presentation Details Title: A phase 1 study of OP-3136, a novel oral selective KAT6A/B inhibitor, as monotherapy and in combination with endocrine therapy (ET) in estrogen receptor-positive (ER+), human epidermal growth factor-2-negative (HER2-) advanced breast cancer (ABC) Abstract Number: 3363 Presentation Number: P1-4-16 Date/Time: Wednesday, December 9, 2026, 12:30 PM – 2:00 PM CT/11:30 AM – 1:00 PM ET

Title: Palazestrant (OP-1250) in combination with everolimus, a phase 1b/2 study, in patients with estrogen receptor-positive, human epidermal growth factor receptor 2-negative (ER+, HER2-) advanced or metastatic breast cancer Abstract Number: 813 Presentation Number: P4-13-28 Date/Time: Thursday, December 10, 2026, 5:00 PM - 6:30 PM CT/6:00 PM - 7:30 PM ET

Title: Palazestrant (OP-1250) in combination with atirmociclib, a phase 1b study, in patients with estrogen receptor-positive, human epidermal growth factor receptor 2-negative (ER+, HER2-) advanced or metastatic breast cancer Abstract Number: 811 Presentation Number: PS10-11 Date/Time: Friday, December 11, 2026, 7:00 AM - 8:30 AM CT/8:00 AM - 9:30 AM ET

Additional information can be found on the SABCS website. A copy of the posters will be made available on the Publications page of Olema’s website in alignment with the SABCS 2026 embargo policy.

About Olema Oncology Olema Oncology is a clinical-stage biopharmaceutical company committed to transforming the standard of care and improving outcomes for patients living with breast cancer and beyond. Olema is advancing a pipeline of novel therapies by leveraging our deep understanding of endocrine-driven cancers, nuclear receptors, and mechanisms of acquired resistance. Our lead product candidate, palazestrant (OP-1250), is a proprietary, orally available complete estrogen receptor antagonist (CERAN) and a selective estrogen receptor degrader (SERD), currently in two Phase 3 clinical trials. In addition, Olema is developing OP-3136, a potent lysine acetyltransferase 6 (KAT6) inhibitor, now in a Phase 1 clinical study. Olema is headquartered in San Francisco and has operations in Cambridge, Massachusetts. For more information, please visit www.olema.com.

About Palazestrant (OP-1250) Palazestrant (OP-1250) is a novel, orally available small molecule with dual activity as both a complete estrogen receptor antagonist (CERAN) and selective estrogen receptor degrader (SERD). It is currently being investigated in patients with recurrent, locally advanced or metastatic ER-positive (ER+), human epidermal growth factor receptor 2-negative (HER2-) breast cancer. In clinical studies, palazestrant completely blocks ER-driven transcriptional activity in both wild-type and mutant forms of metastatic ER+ breast cancer and has demonstrated anti-tumor efficacy along with attractive pharmacokinetics and exposure, favorable tolerability, central nervous system penetration, and combinability with cyclin-dependent kinase 4/6 (CDK4/6) inhibitors. Palazestrant has been granted U.S. Food and Drug Administration (FDA) Fast Track designation for the treatment of ER+/HER2- metastatic breast cancer that has progressed following one or more lines of endocrine therapy with at least one line given in combination with a CDK4/6 inhibitor. It is being evaluated as a single agent in the ongoing pivotal Phase 3 clinical trial, OPERA-01, and in combination with ribociclib in the ongoing pivotal Phase 3 clinical trial, OPERA-02. Palazestrant is also being evaluated in multiple Phase 1/2 studies in combination with ribociclib, palbociclib, alpelisib, everolimus, and atirmociclib.

About OP-3136 OP-3136 is a novel, orally available small molecule that potently and selectively inhibits lysine acetyltransferase 6 (KAT6), an epigenetic target that is dysregulated in breast and other cancers. In preclinical studies, OP-3136 has demonstrated significant anti-proliferative activity in ER+ breast cancer models and is combinable and synergistic with endocrine therapies including palazestrant and cyclin-dependent kinase 4/6 (CDK4/6) inhibitors. The Investigational New Drug (IND) application for OP-3136 was cleared by the U.S. Food and Drug Administration (FDA) in December 2024 and patients are currently enrolling in the Phase 1 clinical study.

Forward-Looking Statements Statements contained in this press release regarding matters that are not historical facts are “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. Words such as “anticipate,” “believe,” “could,” “expect,” “goal,” “intend,” “may,” “on track,” “potential,” “upcoming,” “will” and similar expressions (as well as other words or expressions referencing future events, conditions or circumstances) are intended to identify forward-looking statements. These statements include those related to the potential beneficial characteristics including but not limited to safety, tolerability, activity, efficacy and therapeutic effects of palazestrant and OP-3136, alone, or in combination with each other or with other drugs, including everolimus and atirmociclib. These forward-looking statements are subject to risks and uncertainties, including, without limitation, those discussed in the section titled “Risk Factors” in Olema’s Quarterly Report on Form 10-Q for the quarter ended June 30, 2026, and future filings and reports that Olema makes from time to time with the U.S. Securities and Exchange Commission. Except as required by law, Olema assumes no obligation to update these forward-looking statements, including in the event that actual results differ materially from those anticipated in the forward-looking statements.

Media and Investor Relations Contact Courtney O’Konek Vice President, Corporate Communications Olema Oncology [email protected]

Company Logo

Privacy Preference Center

When you visit any website, it may store or retrieve information on your browser, mostly in the form of cookies. This information might be about you, your preferences or your device and is mostly used to make the site work as you expect it to. The information does not usually directly identify you, but it can give you a more personalized web experience. Because we respect your right to privacy, you can choose not to allow some types of cookies. Click on the different category headings to find out more and change our default settings. However, blocking some types of cookies may impact your experience of the site and the services we are able to offer. More information

Allow All

Manage Consent Preferences

Strictly Necessary Cookies

Always Active

These cookies are necessary for the website to function and cannot be switched off in our systems. They are usually only set in response to actions made by you which amount to a request for services, such as setting your privacy preferences, logging in or filling in forms. You can set your browser to block or alert you about these cookies, but some parts of the site will not then work. These cookies do not store any personally identifiable information.

Performance Cookies

Performance Cookies

These cookies allow us to count visits and traffic sources so we can measure and improve the performance of our site. They help us to know which pages are the most and least popular and see how visitors move around the site. All information these cookies collect is aggregated and therefore anonymous. If you do not allow these cookies we will not know when you have visited our site, and will not be able to monitor its performance.

Targeting Cookies

Targeting Cookies

These cookies may be set through our site by our advertising partners. They may be used by those companies to build a profile of your interests and show you relevant adverts on other sites. They do not store directly personal information, but are based on uniquely identifying your browser and internet device. If you do not allow these cookies, you will experience less targeted advertising.

Cookie List

Clear

checkbox label label

Apply Cancel

Leg.Interest

checkbox label label

checkbox label label

checkbox label label

Reject All

Powered by Onetrust

Prompts

Olema Oncology, Inc. (ticker OLMA), listed in United States.

Company History

Date Change Detail
Nov 12, 2026 Renamed Olema Pharmaceuticals, Inc. → Olema Oncology, Inc.

ETFs Holding Olema Oncology, Inc.

ETF Weight in ETF Shares Market value As of
CANC 0.41% 83,532 $ 871.239K Aug 31, 2026
FMED 0.30% 14,950 $ 155.929K Aug 31, 2026
FESM 0.08% 371,187 $ 4.644M Jun 30, 2026
FSEG 0.06% 286 $ 3,577.86 Jun 30, 2026
FFSM 0.03% 41,085 $ 470.423K Jul 31, 2026
RESM 0.03% 79 $ 988.29 Jun 30, 2026
DFAS 0.01% 568,735 $ 4.277M Nov 12, 2026
MSSM 0.00% 2,239 $ 23.353K Aug 31, 2026
DFAC 0.00% 381,867 $ 2.872M Nov 12, 2026
DCOR 0.00% 101,011 $ 759.603K Nov 12, 2026
DFAU 0.00% 11,994 $ 90.195K Nov 12, 2026
DFUS 0.00% 16,063 $ 120.794K Nov 12, 2026
AVSC 0.00% 4,494 $ 33.076K Nov 16, 2026